Notably, a recent study showed that KRAS-LKB1 mutant lung cancer that often silences the STING pathway is resistant to TTKi and immunotherapy combinations; however, epigenetic drugs can improve response by inducing STING reexpression (51). This evidence concerns the gene KRAS and lung cancer.